Market Access: Pharma

Mock Negotiations and Payer Consultations

Full-service solutions tailored to your needs

Alira Health provides a range of mock negotiation and payer consultation solutions to deliver commercial success, including:
  • Generation of integrated payer evidence and analyses plans to support market access and P&R
  • Preparation and facilitation of international payer-expert advisory boards to optimize development programs and gather insights on product value and evidence requirements
  • Design and facilitation of product value workshops with cross-functional and international teams
  • Payer/Health Technology Assessment (HTA) landscape assessments

Why choose Alira Health?

As your partner, we’ll work closely with you to uncover opportunities across the pharma industry, accelerate innovation, and deliver tomorrow’s standard of care. You’ll benefit from our:

  • Access to a diverse

    integrated team with deep industry expertise

  • Close collaboration

    with our regulatory and clinical

  • Specific, local insights

    as part of your larger, global strategy—a benefit of having market access teams in both the EU and U.S.

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Jean-François Ricci
Jean-François Ricci
Executive Vice President, Global Market Access
Our strong client partnerships allow us to deliver in-depth, customized strategies and access solutions—all designed to maximize product value across its full lifecycle.

Related News

News September 6, 2022
Alira Health Expands North American Capabilities with the Acquisition of Artisan Healthcare Consulting
The acquisition of Artisan strengthens and extends Alira Health’s Market Access and Management Consulting advisory practices in North America and globally.
Biotech Market Access Pharma Therapeutics
Publications August 25, 2022
Why—and When—to Use a CDMO
Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons. In this article, we explore(...)
CDMO Pharma Research and Development
Publications June 23, 2022
Developing Data Specialist Talent: Collaboration Is Key
Companies across Pharma and MedTech need talented people to cover the range of data-related challenges. Discover what this means for developing talent throughout the industry.
Data Specialist MedTech Pharma
News May 11, 2022
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
MedTech Patient Engagement Pharma
News April 5, 2022
Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia
We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)
Clinical MedTech Patient Engagement Pharma Regulatory Research & Development
Publications March 31, 2022
The FDA’s Project Orbis Can Speed up the Delivery of Your New Oncology Drug to Global Markets
Are you developing an oncology drug? Project Orbis, a program coordinated by the U.S. Food and Drug Administration (FDA), allows you to register your product in several countries with(...)
Pharma Regulatory
Events March 4, 2022
Bio Europe Spring 2022
Meet us at Bio Europe Spring 2022. Connect with us to learn how Alira Health can help accelerate innovation and deliver tomorrow’s standard of care.
Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.